Nexus - 1305 - New Times Magazine-pages

Page Content (OCR)

scarring or complete destruction of the nerves and tissues. This may — pharmacology tests were carried out and if no experimental data occur anywhere in the body as the oil-based acid migrates. These were recorded according to medical research procedures, then the symptoms vary greatly in different people, making arachnoiditis manufacturer and importer of this chemical at least committed fraud, difficult to diagnose, with patients often misdiagnosed as having for they received financial gain by deception. As there is no statute chronic fatigue syndrome, asthma, motor neurone disease or of limitations on fraud, this fraud must be investigated by the multiple sclerosis. Sadly, very few people and doctors understand Australian Federal Police and charges laid now. The manufacturer this problem that affects an estimated 100,000 Australians. must be held accountable for its deceitful and misleading statements When we look at others suffering pain we are sympathetic, but we _ on product safety. The law ought to be applied equally without fear cannot understand the pain level they suffer. One mother saidto me __ or favour or discrimination. Where was the government overview that arachnoiditis was like giving birth to her six children all at once, _ and control of the "experimental use only" proviso? 24 hours a day for the last 25 years. If you are a mother who has had a difficult time giving birth, you will have some understanding of the Adverse reactions ignored in Australia pain. Others describe it as a ballistic, nuclear, burning hell; you can Following are some landmark findings on the serious adverse be burning and sweating in winter and freezing in summer, effects of iophendolic acid and its component ingredients (for trembling and shaking so much that you lose control. references, see http://www.arachnoiditis.info/content/pantopaque/ The problem originated with the approval of iophendylate for use sarahs_pantopaque.doc): in Australia, without adequate testing, provision of test data or safety 1928: Odin, Rundstrom and Lindblom (Sweden) published a guarantee required from the manufacturer. The Commonwealth paper on their findings of acute reaction to iodised oils. Health Department approved the drug on no proven safety basis. 1932: The American Medical Association issued a warning about The US Food and Drug Administration (FDA) only ever licensed the long-term risks of introduction of foreign oily compounds into the iophendylate drug Pantopaque for the spinal fluid for imaging purposes. one use, registering it on 22 February 1938: Mettier and Leake also 1944. The chemical formula described adverse reactions to Lipiodol Pantopaque was thus introduced in (iodised oil). 1944, but it was banned in Sweden in iditi i 1940: Neurologist Eric Oldber. 1948, in the United States in 1957 and Arachnoiditis patients are (US) wrote of similar findings. . in the UK by 1990. It was never often misdiagnosed as having 1930s—40s: Neuroradiologists in licensed anywhere else. The chronic fatigue syndrome, Stockholm, working with the famous manufacturers manipulated this neurosurgeon Olivecrona, saw patients product into hospital use throughout asthma, motor neurone disease from all over the world who had the world on product liability i i previously undergone oil-based statements which constituted fraud, or multiple sclerosis. myelography and had sustained affecting millions of people arachnoiditis as a result; they also had worldwide. These statements stated residual dye in the spine and head. It the chemical is safe for human use, but appears that as early as 1935, a hundreds of medical papers now show it decision not to use oil-based contrast is not. media was taken by leading Swedish neuroradiologists. Pre-licence Iophendylate is corrosive: it dissolves paint, linoleum, rubber, studies of the new dye, ethyl iodophenylundecylate (iophendylate), glue, cork tiles and polystyrene coffee cups. Injecting it into demonstrated chemical meningitis similar to that seen by various people's spinal canals where it corrodes the nerves and spinal cord authors. Strain and Warren had already conducted animal studies on and wreaks havoc throughout the body and brain is stupidity straight the new dye, which had originally been synthesised by Plati in out of a Nazi horror movie. Test your imagination: you are being 1937-38. These clearly demonstrated that the compound was not very slowly cut in half from the bottom to the top with a carpenter's absorbed by the body but remained permanently encysted within the power saw—if that makes you feel a little uneasy and squeamish, spinal column and could thus trigger inflammatory reaction and you're getting close to what many arachnoiditis sufferers go through _fibrosis. 24 hours a day, seven days a week. 1941; Markovich, Walker and Jessico studied the effect of Iophendylate came to be used in Australia under what is termeda _iodised oil on the meninges and published their findings in the "grandfathered" agreement, i.e., it is being used in three or more prestigious journal JAMA. They stated that "after the injection of other countries, so it was unlicensed. It was imported into Australia _iodised oil...the oil becomes rapidly encysted by proliferation of the under the Pantopaque brand name between 1974 and 1978, but was arachnoid membrane". approved for experimental use only, licensed on a restricted basis to 1952: Erickson et al. published a case report of a fatality after four hospitals. The importer of Pantopaque was licensed to import — Pantopaque myelography, due to obstructive hydrocephalus. 150 units; in contravention of the import permit, 13,500 units were 1953: Schurr et al. described meningeal irritation due to imported into Australia. Pantopaque. According to independent researcher Derek Morrison, in June 1956: An important paper by Davies was published which 1978 the Australian Therapeutic Goods Board advised that the detailed findings in 124 patients at surgery and up to a year after company which imported and distributed Pantopaque (allegedly Mr — myelography; 60% showed immediate reaction and 12% developed Ernie Hughes) "was involved in unauthorised distribution of the "chronic adhesive meningitis". product". 1960: Whilst Taren published a report of raised intracranial All experiments have procedural requirements to be followed. pressure and multiple cranial nerve palsies after Pantopaque Where are the signed informed-consent forms of the victims? myelography, labelling was approved by the FDA in America. Where is the experimental documentation? Where are the 1962: Mason and Raaf reported a case of obliteration of the pharmacology and pathology test results and data sheets? If no subarachnoid space by Pantopaque-induced arachnoiditis. pharmacology tests were carried out and if no experimental data were recorded according to medical research procedures, then the manufacturer and importer of this chemical at least committed fraud, for they received financial gain by deception. As there is no statute of limitations on fraud, this fraud must be investigated by the Australian Federal Police and charges laid now. The manufacturer must be held accountable for its deceitful and misleading statements on product safety. The law ought to be applied equally without fear or favour or discrimination. Where was the government overview and control of the "experimental use only" proviso? often misdiagnosed as having chronic fatigue syndrome, a en an 5 Vn Ee | 34 = NEXUS Arachnoiditis patients are asthma, motor neurone disease or multiple sclerosis. www.nexusmagazine.com AUGUST — SEPTEMBER 2006